Study S000427

Tirzepatide to Reduce Recurrence and Burden After Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07382024
Acronym: TREAT-AF
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 200
Start: 2026-06-16
Primary completion: 2027-12-31
Lead sponsor: National Taiwan University Hospital
Conditions: Atrial Fibrillation Ablation; Persistent Atrial Fibrillation; Obesity & Overweight
Interventions: DRUG:Tirzepatide; OTHER:Standard Care (in control arm)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Atrial fibrillation burden at 3 months after catheter ablation [3 months after catheter ablation (7-day ECG patch monitoring period)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.